Please assess the completion status of the following clinical trial:

Trial Title: A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1.Subjects receiving laryngeal mask airway-assisted diagnostic and/or therapeutic fiberoptic bronchoscopy; 2.Male or female, ASA I-III, ≥ 18 and \< 80 years old; 3.Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2; 4.Respiratory rate ≥ 10 and ≤ 24 bpm; SpO2 ≥ 93%; SBP ≥ 90 mmHg; DBP ≥ 55 mmHg; HR ≥ 50 and ≤ 100 bpm during screening and baseline periods; 5.Capable of understanding the procedure and method of this study, willing to sign an informed consent form and to complete this study in strict accordance with the study protocol.~-~Exclusion Criteria:~1. Patients with contraindications to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents;~2. Patient known to be allergic to eggs, soy products, opioids and their antidotes, and propofol; patient having contraindications to propofol, opioids and their antidotes;~3. Patients who have undergone endotracheal intubation and/or mechanical ventilation prior to diagnostic or therapeutic bronchoscopy;~4. Medical history or evidence of any of the following prior to screening/at baseline, which may increase sedation/anesthesia risk:~   1. History of cardiovascular diseases: uncontrolled hypertension \[systolic blood pressure (SBP) ≥170 mmHg and/or diastolic blood pressure (DBP) ≥105 mmHg without treatment, or SBP \> 160 mmHg and/or DBP \>100 mmHg after antihypertensive treatment\], aneurysm, severe arrhythmia, heart failure, Adams-stokes syndrome, New York Heart Association (NYHA) Class ≥ III, severe superior vena cava syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medical treatment, II-III degree atrioventricular block (excluding patients with pacemakers) or QTcF interval ≥ 450 ms \[during screening only (corrected using Fredericia's formula1)\];~  2. History of respiratory diseases: severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, throat mass, history of tracheoesophageal fistula or airway tear, severe respiratory infection within 2 weeks prior to screening;~  3. History of neurological and psychiatric disorders: craniocerebral injury, possible convulsions, intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents; schizophrenia, mania, insanity, long-term use of psychotropic drugs, and history of cognitive dysfunction;~  4. History of gastrointestinal diseases: gastrointestinal retention, active hemorrhage, or history of gastroesophageal reflux or obstruction that may lead to aspiration;~  5. History of uncontrolled clinically significant liver, kidney, blood system, nervous system or metabolic system diseases judged by the investigator to be probably unsuitable for involvement in the study;~  6. History of alcohol abuse within 3 months prior to screening, abuse defined as average of \> 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine);~  7. History of drug abuse within 3 months prior to screening;~  8. History of blood transfusion within 14 days prior to screening;~5. Patients with the following respiratory risks during screening/at baseline:~   1. Acute asthma attack;~  2. Sleep apnea syndrome;~  3. History of malignant hyperthermia or family history;~  4. History of failed tracheal intubation;~  5. Difficult airway (modified Mallampati score ≥ III) as determined by the investigator;~6. Patient who received any of the following medications or treatments during screening/at baseline:~   1. Received any investigational drug within 1 month prior to screening;~  2. Received propofol, other sedatives/anesthetics, and/or opioid analgesics or compounds containing analgesics within 72 h prior to baseline;~7. Laboratory results meeting any of the following criteria during screening/at baseline, confirmed by re-examination:~   1. WBC ≤ 3.0 × 10\^9/L;~  2. Platelets ≤ 80 × 10\^9/L;~  3. Hemoglobin ≤ 80 g/L;~  4. Prothrombin time ≥ 1.5 × ULN;~  5. Activated partial thromboplastin time (aPTT) ≥ 1.5 × ULN;~  6. ALT and/or AST ≥ 3 × ULN;~  7. Total bilirubin ≥ 1.5 × ULN;~  8. Serum creatinine ≥ 1.5 × ULN.~8. Women who are pregnant or breastfeeding; women of child-bearing potential or men who are unwilling to use contraception during the trial; or subjects who are planning pregnancy within 3 month after the completion of the trial (including male subjects);~9. Subject judged by the investigator to have any other factors unsuitable for involvement in the study.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HSK3486 (Type: EXPERIMENTAL): Subjects \< 65 years old:0.4mg/kg/0.15mg/kg;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
- Propofol (Type: ACTIVE_COMPARATOR): Subjects \< 65 years old:2mg/kg/0.75mg/kg;Subjects≥ 65 years old:75% of the dose for subjects \< 65 years old.

Based on this trial design, predict the completion outcome and termination type (if applicable).